| Code Compliance Promotion Committee |
The JCIA promotes compliance among member companies, manages and operates the JCIA Code of Practice, and supports member companies in their activities to promote compliance with the Code. |
| Product Information Summary Review Meeting |
To promote the proper use of ethical pharmaceuticals, the MMA conducts self-examinations of promotional materials such as product information summaries and advertisements in professional journals for ethical pharmaceuticals prepared by member companies. |
| Industry Policy Committee |
In order to promptly respond to changes in the environment surrounding the pharmaceutical industry, the committee examines issues and makes policy proposals regarding industry promotion, innovation promotion, taxation, elimination of tariffs on pharmaceuticals*, and other issues that cannot be addressed by the standing committees.
|
| Distribution Appropriateness Committee |
In order to achieve transparency and efficiency in the distribution of pharmaceuticals, the committee works to resolve various issues through consultations with related organizations and the government, and makes policy proposals as the Pharmaceutical Manufacturers Association of Japan (PMAJ). |
| Drug Evaluation Committee |
In order to promote pharmaceutical research, development, post-marketing safety and proper use, and medical affairs activities, the Drug Evaluation Committee examines technologies and regulations in each of these activities, makes policy recommendations, and conducts educational activities. |
| Quality Committee |
The Pharmaceutical Quality Forum is a forum for research and study of pharmaceutical GMP, manufacturing and analytical techniques, and related issues from an international perspective, as well as for the establishment and active promotion of measures to improve the reliability of pharmaceutical quality, thereby contributing to the improvement of medical care and the sound development of the industry. |
| Biopharmaceutical Committee |
The Biopharmaceutical Committee makes policy recommendations on the development of infrastructure for the promotion of biopharmaceutical research and development. The committee also conducts surveys and research on various technical issues related to biopharmaceuticals, from research and development to production and post-marketing activities, and makes recommendations for improvement to the government and other relevant agencies. |
| Regulatory Affairs Committee |
The committee studies and examines various issues in the operation of the Pharmaceuticals and Medical Devices Act system and various pharmaceutical regulatory matters related to drug approval screening and safety measures, etc., and makes policy recommendations on various pharmaceutical administration matters, such as improving the efficiency of corporate activities and expediting approval screening, from the standpoint of R&D-oriented pharmaceutical companies. |
| Intellectual Property Committee |
In order for Japan's pharmaceutical industry to maintain its competitiveness in the international economic community and to continue to develop, the committee works with relevant ministries, agencies, and other organizations to actively make policy proposals regarding intellectual property systems not only in Japan but around the world. The committee also disseminates information to promote understanding of intellectual property issues in the life science field. |
| Research and Development Committee |
The International Trade Committee aims to realize effective drug discovery R&D for member companies by collecting and sharing information on key issues from the research stage to non-clinical and clinical trials, making policy recommendations to the Japan Agency for Medical Research and Development (AMED) and government ministries and agencies, and promoting open innovation. |
| International Committee |
From the three perspectives of international expansion, international harmonization, and contribution to global health, the International Committee deepens cooperation with regulatory authorities, pharmaceutical organizations, and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in various countries and conducts activities to resolve international issues faced by the industry and member companies. |
| Public Relations Committee |
The committee develops activities to raise awareness and gain correct understanding of pharmaceuticals and the pharmaceutical industry. The committee also promotes proactive public relations activities to realize the policy proposals advocated by the Pharmaceutical Manufacturers Association of Japan (PAPJ). |
| Patient Organization Collaboration Promotion Committee |
We will actively exchange opinions with patient groups to promote mutual understanding, consider initiatives from the patients' perspective, and work together better with patient groups. In addition, we will make efforts to disseminate the "Transparency Guidelines for Relationships between Corporate Activities and Patient Organizations". |
| ICH Project |
The Foundation participates in the International Conference on Harmonization of Pharmaceutical Regulations (ICH) and conducts activities to speed up and improve the efficiency of drug development through the creation of common guidelines. In addition, the Foundation will hold ICH immediate debriefing sessions and guideline briefing sessions, etc., and strive to disseminate information on ICH. |
| APAC Project |
The Asian Pharmaceutical Alliance Council (APAC) is a platform consisting of 14 research-based pharmaceutical organizations in Asia to identify issues and make recommendations toward the realization of the mission of "bringing innovative medicines to the people of Asia in a timely manner. The APAC aims to create results to achieve the mission through discussions with government and academia on the defined themes through studies and deliberations by each of the related working groups and task forces. |
| Pharmaceutical Counseling and Response Review Committee |
The committee aims to contribute to "patient-participatory medicine" by improving the reliability of the information provided and the recognition as a consultation service by studying and making proposals on how pharmaceutical information should be provided to the public and how a corporate consultation service for pharmaceuticals should be provided. |
| Environmental Issues Review Committee |
The Environmental Issues Study Group is responsible for studying measures to promote responses to various issues related to global environmental protection, and aims to promote environmental protection activities. |
